Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719459 | 0.85 | AGTR2 (0.54) | AGTR2CYP3A4 | |
| SCHEMBL1719583 | 0.85 | AGTR2 (1.00) | AGTR2CYP3A4 | |
| SCHEMBL1718916 | 0.83 | AGTR2 (0.71) | AGTR2CYP3A4 | |
| SCHEMBL1718556 | 0.83 | AGTR2 (0.60) | AGTR2CYP3A4 | |
| SCHEMBL1718906 | 0.80 | AGTR2 (0.59) | AGTR2CYP3A4 | |
| SCHEMBL25254599 | 0.79 | AGTR2 (0.48) | AGTR2CYP3A4 | |
| SCHEMBL1719937 | 0.78 | AGTR2 (0.56) | AGTR2CYP3A4 | |
| SCHEMBL26129333 | 0.78 | AGTR2 (0.46) | AGTR2CYP3A4 | |
| SCHEMBL1718934 | 0.77 | AGTR2 (0.56) | AGTR2CYP3A4 | |
| SCHEMBL1718991 | 0.77 | AGTR2 (0.57) | AGTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869023-B1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-8080571-B2 | Tricyclic angiotensin II agonists | VICORE PHARMA AB (SE) | 2011-12-20 | — | — | US | disclosed |
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | VICORE PHARMA AB (SE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885CYP3A4 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.